Hydroxychloroquine use in the Baltimore Lupus Cohort: Effects on lipids, glucose and thrombosis

Research output: Contribution to journalShort surveypeer-review

Abstract

Hydroxychloroquine is used by 35% of SLE patients enrolled in the Baltimore Lupus Cohort. Eighty per cent of patients who took hydroxychloroquine at cohort entry remain on it six years later. In addition to its role for disease manifestations of lupus, hydroxychloroquine may be indicated for the prevention of disease or treatment-induced complications, including hyperlipidemia, diabetes mellitus, liver function test elevation and thrombosis.

Original languageEnglish (US)
Pages (from-to)S16-S22
JournalLupus
Volume5
Issue numberSUPPL. 1
DOIs
StatePublished - 1996

Keywords

  • Diabetes mellitus
  • Hydroxychloroquine
  • Hyperlipidemia
  • Liver function tests
  • Thrombosis

ASJC Scopus subject areas

  • Rheumatology

Fingerprint

Dive into the research topics of 'Hydroxychloroquine use in the Baltimore Lupus Cohort: Effects on lipids, glucose and thrombosis'. Together they form a unique fingerprint.

Cite this